

In the specification:

Please replace the last paragraph on page 5, beginning at line 22 with the following:

Also provided by the present invention are methods of diagnosis using stabilized glycoproteins, such as immunoglobulins, proteins and other bioactive molecules. In a specific embodiment, the invention provides a stabilized anti-respiratory syncytial virus (RSV) antibody useful to treat or prevent RSV infection, such as a stabilized form of SYNAGIS® (palivizumab) (see U.S. Patent No. 5,824,307 and Johnson *et al.*, *J. Infectious Disease* 176:1215-1224, 1997, both of which are incorporated by reference in their entireties), and other anti-RSV antibodies, including variants of SYNAGIS® (see United States patent Application Serial No., 09/724,396, filed November 28, 2000, United States patent Application Serial No. 09/724,531, filed November 28, 2000, United States patent Application Serial No. 09/996,288 filed November 28, 2001, and United States patent Application Serial No. 09/996,265 filed November 28, 2001, all entitled “Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis and Treatment,” all by Young *et al.*, all of which are incorporated by reference herein in their entireties, particularly the sequences of heavy and light chain variable domains and CDRs of anti-RSV antibodies disclosed therein). In a preferred embodiment, a stabilized anti-RSV antibody has one or more amino acid modifications in the heavy chain constant domain hinge region that renders the antibody less susceptible to degradation.